Information Provided By:
Fly News Breaks for January 21, 2020
Jan 21, 2020 | 06:23 EDT
Piper Sandler analyst Christopher Raymond named Ardelyx a top small cap pick for 2020 despite the stock's strong 2019. The analyst highlights continued positive nephrologist feedback regarding the company's lead drug tenapanor. Both nephrologists and renal dieticians highlight a significant unmet need in phosphorus control, high awareness and anticipation of commercial availability of tenapanor, and an increasing view that tenapanor will be used first-line, Raymond tells investors in a research note. He believes Ardelyx shares could double and keeps an Overweight rating on the name with a $15 price target.
News For ARDX From the Last 2 Days
Dec 1, 2021 | 09:40 EST
Unusual total active option classes on open include: Ardelyx (ARDX), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Vertex Energy (VTNR), 180 Life Sciences (ATNF), XPeng (XPEV), Li Auto (LI), Altimeter Growth Corp (AGC), Cameco (CCJ), and Merck (MRK).
Nov 30, 2021 | 10:39 EST
Piper Sandler analyst Christopher Raymond keeps a Neutral rating on Ardelyx, with a price target of $4, following management's announced plans to launch Ibsrela in IBS-C. FDA approved Ibsrela back in September, 2019, but the opportunity was shelved as management had indicated the undifferentiated clinical profile, coupled with the large expense of launching in this market required that Ardelyx find a partner, the analyst adds. Raymond understands investors may be skeptical of this sequence of events. That said, he is "willing to listen" and thinks it makes sense to do some of his own work on this opportunity.